vs

Side-by-side financial comparison of Adaptive Biotechnologies Corp (ADPT) and Cardlytics, Inc. (CDLX). Click either name above to swap in a different company.

Adaptive Biotechnologies Corp is the larger business by last-quarter revenue ($70.9M vs $50.9M, roughly 1.4× Cardlytics, Inc.). On growth, Adaptive Biotechnologies Corp posted the faster year-over-year revenue change (35.1% vs -25.5%). Over the past eight quarters, Adaptive Biotechnologies Corp's revenue compounded faster (28.1% CAGR vs -9.6%).

ExpreS2ion Biotechnologies is a Danish biotechnology company specialised in the development of new vaccines and immunotherapy products based in Hørsholm, Denmark and listed on the Nasdaq First North Growth Market Sweden.

Cardlytics is a leading purchase intelligence and advertising platform that partners with major banks to analyze anonymized consumer transaction data. It delivers targeted, performance-driven ad campaigns for consumer brands, retailers and service providers, helping advertisers reach audiences based on real purchase behavior, with core operations across North America and the United Kingdom.

ADPT vs CDLX — Head-to-Head

Bigger by revenue
ADPT
ADPT
1.4× larger
ADPT
$70.9M
$50.9M
CDLX
Growing faster (revenue YoY)
ADPT
ADPT
+60.6% gap
ADPT
35.1%
-25.5%
CDLX
Faster 2-yr revenue CAGR
ADPT
ADPT
Annualised
ADPT
28.1%
-9.6%
CDLX

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
ADPT
ADPT
CDLX
CDLX
Revenue
$70.9M
$50.9M
Net Profit
$3.4M
Gross Margin
73.6%
Operating Margin
-27.1%
-12.0%
Net Margin
4.7%
Revenue YoY
35.1%
-25.5%
Net Profit YoY
EPS (diluted)
$-0.15

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ADPT
ADPT
CDLX
CDLX
Q1 26
$70.9M
Q4 25
$71.7M
$50.9M
Q3 25
$94.0M
$47.0M
Q2 25
$58.9M
$58.0M
Q1 25
$52.4M
$56.4M
Q4 24
$47.5M
$68.3M
Q3 24
$46.4M
$61.1M
Q2 24
$43.2M
$64.0M
Net Profit
ADPT
ADPT
CDLX
CDLX
Q1 26
$3.4M
Q4 25
$-13.6M
Q3 25
$9.5M
$-72.7M
Q2 25
$-25.6M
$-9.3M
Q1 25
$-29.9M
$-13.3M
Q4 24
$-33.7M
Q3 24
$-32.1M
$-145.2M
Q2 24
$-46.2M
$-4.3M
Gross Margin
ADPT
ADPT
CDLX
CDLX
Q1 26
73.6%
Q4 25
74.6%
Q3 25
80.7%
Q2 25
69.4%
Q1 25
67.6%
Q4 24
62.0%
Q3 24
64.1%
Q2 24
55.3%
Operating Margin
ADPT
ADPT
CDLX
CDLX
Q1 26
-27.1%
Q4 25
-17.8%
-12.0%
Q3 25
10.9%
-146.6%
Q2 25
-42.5%
-22.0%
Q1 25
-56.4%
-24.9%
Q4 24
-71.3%
-12.2%
Q3 24
-70.3%
-243.1%
Q2 24
-109.6%
-24.7%
Net Margin
ADPT
ADPT
CDLX
CDLX
Q1 26
4.7%
Q4 25
-18.9%
Q3 25
10.2%
-154.7%
Q2 25
-43.5%
-16.0%
Q1 25
-56.9%
-23.5%
Q4 24
-71.0%
Q3 24
-69.1%
-237.6%
Q2 24
-107.0%
-6.7%
EPS (diluted)
ADPT
ADPT
CDLX
CDLX
Q1 26
Q4 25
$-0.08
$-0.15
Q3 25
$0.06
$-1.36
Q2 25
$-0.17
$-0.18
Q1 25
$-0.20
$-0.26
Q4 24
$-0.22
$-0.36
Q3 24
$-0.22
$-2.90
Q2 24
$-0.31
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ADPT
ADPT
CDLX
CDLX
Cash + ST InvestmentsLiquidity on hand
$77.6M
$48.7M
Total DebtLower is stronger
$212.6M
Stockholders' EquityBook value
$-6.5M
Total Assets
$505.9M
$285.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ADPT
ADPT
CDLX
CDLX
Q1 26
$77.6M
Q4 25
$70.5M
$48.7M
Q3 25
$55.0M
$44.0M
Q2 25
$43.2M
$46.7M
Q1 25
$50.6M
$52.0M
Q4 24
$47.9M
$65.6M
Q3 24
$38.1M
$67.0M
Q2 24
$59.8M
$71.2M
Total Debt
ADPT
ADPT
CDLX
CDLX
Q1 26
Q4 25
$212.6M
Q3 25
$214.6M
Q2 25
$214.3M
Q1 25
$213.9M
Q4 24
$213.6M
Q3 24
$213.2M
Q2 24
$212.9M
Stockholders' Equity
ADPT
ADPT
CDLX
CDLX
Q1 26
Q4 25
$218.8M
$-6.5M
Q3 25
$204.4M
$-4.7M
Q2 25
$179.7M
$58.7M
Q1 25
$190.4M
$64.1M
Q4 24
$202.7M
$70.0M
Q3 24
$223.8M
$69.7M
Q2 24
$241.6M
$210.0M
Total Assets
ADPT
ADPT
CDLX
CDLX
Q1 26
$505.9M
Q4 25
$512.7M
$285.6M
Q3 25
$490.6M
$292.8M
Q2 25
$496.6M
$361.1M
Q1 25
$510.9M
$369.1M
Q4 24
$539.4M
$392.7M
Q3 24
$558.5M
$399.4M
Q2 24
$584.9M
$534.4M
Debt / Equity
ADPT
ADPT
CDLX
CDLX
Q1 26
Q4 25
Q3 25
Q2 25
3.65×
Q1 25
3.34×
Q4 24
3.05×
Q3 24
3.06×
Q2 24
1.01×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ADPT
ADPT
CDLX
CDLX
Operating Cash FlowLast quarter
$13.0M
Free Cash FlowOCF − Capex
$13.0M
FCF MarginFCF / Revenue
25.5%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$8.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ADPT
ADPT
CDLX
CDLX
Q1 26
Q4 25
$2.1M
$13.0M
Q3 25
$-7.1M
$1.8M
Q2 25
$-12.4M
$1.2M
Q1 25
$-28.5M
$-6.7M
Q4 24
$-12.5M
$3.0M
Q3 24
$-27.1M
$1.4M
Q2 24
$-17.3M
$4.4M
Free Cash Flow
ADPT
ADPT
CDLX
CDLX
Q1 26
Q4 25
$1.4M
$13.0M
Q3 25
$-7.5M
$1.7M
Q2 25
$-13.1M
$903.0K
Q1 25
$-29.7M
$-6.8M
Q4 24
$-12.6M
$2.9M
Q3 24
$-27.4M
$878.0K
Q2 24
$-19.0M
$4.1M
FCF Margin
ADPT
ADPT
CDLX
CDLX
Q1 26
Q4 25
2.0%
25.5%
Q3 25
-8.0%
3.7%
Q2 25
-22.2%
1.6%
Q1 25
-56.7%
-12.1%
Q4 24
-26.5%
4.2%
Q3 24
-59.0%
1.4%
Q2 24
-44.1%
6.5%
Capex Intensity
ADPT
ADPT
CDLX
CDLX
Q1 26
Q4 25
0.9%
0.0%
Q3 25
0.4%
0.0%
Q2 25
1.1%
0.6%
Q1 25
2.4%
0.2%
Q4 24
0.2%
0.2%
Q3 24
0.7%
0.8%
Q2 24
4.0%
0.4%
Cash Conversion
ADPT
ADPT
CDLX
CDLX
Q1 26
Q4 25
Q3 25
-0.75×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons